Announcements Trials
Browse Landscape

Clinical Trials

1 trials
RecentStart dateEnrollment
NX-13 × Clear all

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Colitis, Ulcerative 1

Interventions

Cisplatin 3180Cyclophosphamide 3173Carboplatin 2960Radiotherapy 2772Paclitaxel 2708Gemcitabine 2552pembrolizumab 2370Bevacizumab 2195Docetaxel 2191Fluorouracil 1839Capecitabine 1815Oxaliplatin 1724Dexamethasone 1593Nivolumab 1577Doxorubicin 1501Rituximab 1480Magnetic Resonance Spectroscopy 1368Etoposide 1344Irinotecan 1241Leucovorin 1217Drug Therapy 1190Cytarabine 1127Pemetrexed 1068fludarabine 1035Specimen Handling 987Vincristine 964Prednisone 940Cetuximab 939Trastuzumab 937Lenalidomide 932

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT05785715 2025-07-01

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

AbbVie

Phase 2 Terminated
81 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡